Lornoxicam

DB06725

small molecule approved investigational

Deskripsi

Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.

Struktur Molekul 2D

Berat 371.81
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 3-5 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Lornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%).

Metabolisme

Lornoxicam is metabolized completely by cyp 2C9 with the principal metabolite being 5'-hydroxy-lornoxicam and only negligible amounts of intact lornoxicam are excreted unchanged in the urine. Approximately 2/3 of the drug is eliminated via the liver and 1/3 via the kidneys in the active form.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1558 Data
Amlodipine The metabolism of Lornoxicam can be decreased when combined with Amlodipine.
Phentermine The risk or severity of hypertension can be increased when Phentermine is combined with Lornoxicam.
Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Lornoxicam.
Isoetharine The risk or severity of hypertension can be increased when Isoetharine is combined with Lornoxicam.
Ziprasidone The risk or severity of hypertension can be increased when Ziprasidone is combined with Lornoxicam.
Methysergide The risk or severity of hypertension can be increased when Methysergide is combined with Lornoxicam.
Cabergoline The risk or severity of hypertension can be increased when Cabergoline is combined with Lornoxicam.
Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Lornoxicam.
Dihydroergotamine The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Lornoxicam.
Methylergometrine The risk or severity of hypertension can be increased when Methylergometrine is combined with Lornoxicam.
Norepinephrine The risk or severity of hypertension can be increased when Norepinephrine is combined with Lornoxicam.
Mirtazapine The risk or severity of hypertension can be increased when Mirtazapine is combined with Lornoxicam.
Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Lornoxicam.
Phenylpropanolamine The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Lornoxicam.
Droperidol The risk or severity of hypertension can be increased when Droperidol is combined with Lornoxicam.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Lornoxicam.
Atropine The risk or severity of hypertension can be increased when Atropine is combined with Lornoxicam.
Lisuride The risk or severity of hypertension can be increased when Lisuride is combined with Lornoxicam.
Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Lornoxicam.
Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with Lornoxicam.
Furazolidone The risk or severity of hypertension can be increased when Furazolidone is combined with Lornoxicam.
Thioridazine The risk or severity of hypertension can be increased when Thioridazine is combined with Lornoxicam.
Ergotamine The risk or severity of hypertension can be increased when Ergotamine is combined with Lornoxicam.
Nicergoline The risk or severity of hypertension can be increased when Nicergoline is combined with Lornoxicam.
Sufentanil The risk or severity of hypertension can be increased when Sufentanil is combined with Lornoxicam.
Methoxamine The risk or severity of hypertension can be increased when Methoxamine is combined with Lornoxicam.
Risperidone The risk or severity of hypertension can be increased when Risperidone is combined with Lornoxicam.
Isoflurane The risk or severity of hypertension can be increased when Isoflurane is combined with Lornoxicam.
Propiomazine The risk or severity of hypertension can be increased when Propiomazine is combined with Lornoxicam.
Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Lornoxicam.
Minaprine The risk or severity of hypertension can be increased when Minaprine is combined with Lornoxicam.
Orciprenaline The risk or severity of hypertension can be increased when Orciprenaline is combined with Lornoxicam.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Lornoxicam.
Trifluoperazine The risk or severity of hypertension can be increased when Trifluoperazine is combined with Lornoxicam.
Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Lornoxicam.
Benzphetamine The risk or severity of hypertension can be increased when Benzphetamine is combined with Lornoxicam.
Ritodrine The risk or severity of hypertension can be increased when Ritodrine is combined with Lornoxicam.
Flupentixol The risk or severity of hypertension can be increased when Flupentixol is combined with Lornoxicam.
Remifentanil The risk or severity of hypertension can be increased when Remifentanil is combined with Lornoxicam.
Bitolterol The risk or severity of hypertension can be increased when Bitolterol is combined with Lornoxicam.
Oxymetazoline The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lornoxicam.
Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with Lornoxicam.
Salmeterol The risk or severity of hypertension can be increased when Salmeterol is combined with Lornoxicam.
Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Lornoxicam.
Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with Lornoxicam.
Ergoloid mesylate The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Lornoxicam.
Isoprenaline The risk or severity of hypertension can be increased when Isoprenaline is combined with Lornoxicam.
Arbutamine The risk or severity of hypertension can be increased when Arbutamine is combined with Lornoxicam.
Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Lornoxicam.
Pergolide The risk or severity of hypertension can be increased when Pergolide is combined with Lornoxicam.
Desflurane The risk or severity of hypertension can be increased when Desflurane is combined with Lornoxicam.
Bromocriptine The risk or severity of hypertension can be increased when Bromocriptine is combined with Lornoxicam.
Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with Lornoxicam.
Aripiprazole The risk or severity of hypertension can be increased when Aripiprazole is combined with Lornoxicam.
Isocarboxazid The risk or severity of hypertension can be increased when Isocarboxazid is combined with Lornoxicam.
Ergometrine The risk or severity of hypertension can be increased when Ergometrine is combined with Lornoxicam.
Lisdexamfetamine The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Lornoxicam.
Fenoterol The risk or severity of hypertension can be increased when Fenoterol is combined with Lornoxicam.
Pirbuterol The risk or severity of hypertension can be increased when Pirbuterol is combined with Lornoxicam.
Ephedra sinica root The risk or severity of hypertension can be increased when Ephedra sinica root is combined with Lornoxicam.
Ephedrine The risk or severity of hypertension can be increased when Ephedrine is combined with Lornoxicam.
Mephentermine The risk or severity of hypertension can be increased when Mephentermine is combined with Lornoxicam.
Procaterol The risk or severity of hypertension can be increased when Procaterol is combined with Lornoxicam.
Yohimbine The risk or severity of hypertension can be increased when Yohimbine is combined with Lornoxicam.
Methotrimeprazine The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Lornoxicam.
Clenbuterol The risk or severity of hypertension can be increased when Clenbuterol is combined with Lornoxicam.
Bambuterol The risk or severity of hypertension can be increased when Bambuterol is combined with Lornoxicam.
MMDA The risk or severity of hypertension can be increased when MMDA is combined with Lornoxicam.
Midomafetamine The risk or severity of hypertension can be increased when Midomafetamine is combined with Lornoxicam.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Lornoxicam.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Lornoxicam.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Lornoxicam.
Tenamfetamine The risk or severity of hypertension can be increased when Tenamfetamine is combined with Lornoxicam.
Chlorphentermine The risk or severity of hypertension can be increased when Chlorphentermine is combined with Lornoxicam.
Dextroamphetamine The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Lornoxicam.
Phendimetrazine The risk or severity of hypertension can be increased when Phendimetrazine is combined with Lornoxicam.
Solifenacin The risk or severity of hypertension can be increased when Solifenacin is combined with Lornoxicam.
Periciazine The risk or severity of hypertension can be increased when Periciazine is combined with Lornoxicam.
Acepromazine The risk or severity of hypertension can be increased when Acepromazine is combined with Lornoxicam.
Thioproperazine The risk or severity of hypertension can be increased when Thioproperazine is combined with Lornoxicam.
Zuclopenthixol The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Lornoxicam.
Epicaptopril The risk or severity of hypertension can be increased when Epicaptopril is combined with Lornoxicam.
Clorgiline The risk or severity of hypertension can be increased when Clorgiline is combined with Lornoxicam.
1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Lornoxicam.
Nialamide The risk or severity of hypertension can be increased when Nialamide is combined with Lornoxicam.
Lysergic acid diethylamide The risk or severity of hypertension can be increased when Lysergic acid diethylamide is combined with Lornoxicam.
Dronedarone The risk or severity of hypertension can be increased when Dronedarone is combined with Lornoxicam.
Flibanserin The risk or severity of hypertension can be increased when Flibanserin is combined with Lornoxicam.
Iloperidone The risk or severity of hypertension can be increased when Iloperidone is combined with Lornoxicam.
Indacaterol The risk or severity of hypertension can be increased when Indacaterol is combined with Lornoxicam.
Rotigotine The risk or severity of hypertension can be increased when Rotigotine is combined with Lornoxicam.
Amibegron The risk or severity of hypertension can be increased when Amibegron is combined with Lornoxicam.
Naluzotan The risk or severity of hypertension can be increased when Naluzotan is combined with Lornoxicam.
Cariprazine The risk or severity of hypertension can be increased when Cariprazine is combined with Lornoxicam.
Mianserin The risk or severity of hypertension can be increased when Mianserin is combined with Lornoxicam.
Pizotifen The risk or severity of hypertension can be increased when Pizotifen is combined with Lornoxicam.
Solabegron The risk or severity of hypertension can be increased when Solabegron is combined with Lornoxicam.
Asenapine The risk or severity of hypertension can be increased when Asenapine is combined with Lornoxicam.
Esmirtazapine The risk or severity of hypertension can be increased when Esmirtazapine is combined with Lornoxicam.
Vilazodone The risk or severity of hypertension can be increased when Vilazodone is combined with Lornoxicam.

Target Protein

Prostaglandin G/H synthase 1 PTGS1
Prostaglandin G/H synthase 2 PTGS2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 8706598
    Balfour JA, Fitton A, Barradell LB: Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57.
  • PMID: 8630629
    Vane JR: Introduction: mechanism of action of NSAIDs. Br J Rheumatol. 1996 Apr;35 Suppl 1:1-3.
  • PMID: 12879104
    Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76.
  • PMID: 9646006
    Skjodt NM, Davies NM: Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421-8.
  • PMID: 8162655
    Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20.
  • PMID: 2284217
    Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D: Pharmacokinetics of lornoxicam in man. Postgrad Med J. 1990;66 Suppl 4:S22-7.
  • PMID: 2284216
    Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F, Fellier H: Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66 Suppl 4:S18-21.
  • PMID: 8857077
    Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Lorcam — Taisho Pharmaceutical Co.
  • Xafon — Nycomed

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul